Tacrolimus liposomal (Lipella)

他克莫司脂质体 (Lipella)

Report date: 2026/03/04 20:01:44

Base Information

Drug NameTacrolimus liposomal (Lipella)
Drug Alias NameIntravesical tacrolimusLiposomal tacrolimusLP-10LP-310LP-410
ClassificationSmall molecules > Heterocyclic drugsSmall molecules > Molecular Glue
Mechanisms of ActionBone morphogenetic protein receptor type-2 modulatorsCalcineurin inhibitorsCytokines inhibitors +[5] 
TargetsBone morphogenetic protein receptor type-2CalcineurinCytokines
Therapy Area/IndicationsGraft vs Host DiseaseCystitisLichen Planus, Oral
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesLipella Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesLipella Pharmaceuticals Inc
Inactive CompaniesN/A
Active IndicationsGraft vs Host DiseaseCystitisLichen Planus, Oral
Inactive IndicationsN/A

Other Information

ATC CodeD11AH01L04AD02
Related LinksDrugBank